Table 1. Unadjusted OR for characteristics of patients comparing women with men according to age.
| All patients |
Age group, yrs |
||||||
| Men (M) n = 12,562 | Women (W) n = 4459 | P-value | < 60 n = 7079 (M = 6527, W = 552) OR* | 60–69 n = 4050 (M = 3005, W = 1045) | 70–79 n = 4203 (M = 2362, W = 1841) | ≥ 80 n = 1689 (M = 668, W = 1021) | |
| BMI, kg/m2 | < 0.001 | ||||||
| ≥ 25 | 4192 (33.4%) | 1109 (24.9%) | 0.78† | 1.19† | 1.18† | 1.12 | |
| < 25 | 7247 (57.7%) | 2716 (60.9%) | 1.29† | 0.84† | 0.84† | 0.89 | |
| Medical history | |||||||
| Hypertension | 5111 (40.7%) | 2709 (60.8%) | < 0.001 | 2.43† | 1.76† | 1.54† | 1.83† |
| Diabetes mellitus | 2830 (22.5%) | 1341 (30.1%) | < 0.001 | 1.59† | 1.45† | 1.31† | 1.33† |
| Dyslipidemia | 1230 (9.8%) | 399 (8.9%) | 0.124 | 0.97 | 1.33† | 1.33† | 1.25 |
| Current smoking | 7317 (58.2%) | 575 (12.9%) | < 0.001 | 0.09† | 0.14† | 0.23† | 0.25† |
| Previous MI | 745 (5.9%) | 180 (4.0%) | < 0.001 | 0.41† | 0.49† | 0.70† | 0.59† |
| LV ejection fraction, % | < 0.001 | ||||||
| < 40 | 1648 (13.1%) | 689 (15.5%) | 1.12 | 0.92 | 0.92 | 0.79 | |
| ≥ 40 | 9439 (75.1%) | 3148 (70.6%) | 0.89 | 1.09 | 1.09 | 1.27 | |
| Killip class | < 0.001 | ||||||
| ≥ 3 | 1475 (11.7%) | 877 (19.7%) | 1.63† | 1.17 | 1.54† | 1.31† | |
| < 3 | 10212 (81.3%) | 3269 (73.3%) | 0.61† | 0.85 | 0.65† | 0.76† | |
| Door to balloon time, mins | 0.533 | ||||||
| ≥ 90 | 3804 (30.3%) | 1345 (30.2%) | 1.14 | 0.97 | 1.12 | 0.83 | |
| < 90 | 5719 (45.5%) | 1971 (44.2%) | 1.00 | 1.03 | 0.89 | 1.20 | |
| Symptom to balloon time, hours | < 0.001 | ||||||
| < 12 | 8795 (70.0%) | 2903 (65.1%) | 0.78† | 0.92 | 0.89 | 0.94 | |
| > 12 to ≤ 24 | 1226 (9.8%) | 504 (11.3%) | 1.35† | 1.09 | 1.00 | 0.94 | |
| > 24 | 997 (7.9%) | 488 (10.9%) | 1.11 | 1.07 | 1.23† | 1.17 | |
| Laboratory finding | |||||||
| Peak CK-MB, ng/mL | < 0.001 | ||||||
| ≥ 5 | 4641 (36.9%) | 1409 (31.6%) | 0.84 | 0.78† | 0.97 | 0.93 | |
| < 5 | 7685 (61.2%) | 2958 (66.3%) | 1.20 | 1.28† | 1.03 | 1.07 | |
| Peak Troponin-I, ng/mL | < 0.001 | ||||||
| ≥ 0.1 | 2848 (22.7%) | 925 (20.7%) | 0.94 | 0.83† | 0.89 | 0.78 | |
| < 0.1 | 7154 (56.9%) | 2742 (61.5%) | 1.06 | 1.21† | 1.12 | 1.28 | |
| hs-CRP, mg/dL | < 0.001 | ||||||
| ≥ 1 | 1275 (10.1%) | 541 (12.1%) | 1.23 | 1.29† | 0.89 | 0.75† | |
| < 1 | 8670 (69.0%) | 2916 (65.4%) | 0.81 | 0.77† | 1.12 | 1.34† | |
| Creatinine, mg/dL | < 0.001 | ||||||
| ≥ 1.2 | 3755 (29.9%) | 903 (20.3%) | 0.36† | 0.38† | 0.40† | 0.36† | |
| < 1.2 | 8592 (68.4%) | 3490 (78.3%) | 2.79† | 2.61† | 2.49† | 2.79† | |
| LDL cholesterol, mg/dL | < 0.001 | ||||||
| ≤ 130 | 7649 (60.9%) | 2471 (55.4%) | 0.89 | 0.52† | 0.50† | 0.52† | |
| > 130 | 3442 (27.4%) | 1383 (31.0%) | 1.12 | 1.93† | 2.02† | 1.94† | |
| Discharge medication | |||||||
| Aspirin | 11307 (90.0%) | 3703 (83.0%) | 0.087 | 0.87 | 0.82 | 0.79 | 0.65 |
| Clopidogrel | 11038 (87.9%) | 3577 (80.2%) | < 0.001 | 0.51† | 0.70† | 0.68† | 0.80 |
| Statin | 8813 (70.2%) | 2861 (64.2%) | 0.192 | 1.05 | 1.13 | 1.01 | 1.12 |
| Beta blocker | 8869 (70.6%) | 2863 (64.2%) | 0.072 | 0.86 | 1.02 | 1.27† | 1.10 |
| ACEI/ARB | 9498 (75.6%) | 3080 (69.1%) | 0.047 | 0.76† | 0.93 | 1.07 | 0.99 |
*The OR is for the comparison of women with men. †The OR is significant between women and men. Data were presented as n (%). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; CK-MB: creatine kinase-MB; hs-CRP: high sensitivity C-reactive protein; LDL: low density lipoprotein; LV: left ventricular; MI: myocardial infarction; OR: odds ratios.